Clinical Trial Update: Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa [Phase 1]

View source ↗

Summary

Phase I trial evaluating isotretinoin in patients with recessive dystrophic epidermolysis bullosa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa
• Recessive Dystrophic Epidermolysis Bullosa

Drugs mentioned

• ISOTRETINOIN (Isotretinoin)

Snippet

Sponsor: University of North Carolina | Conditions: Epidermolysis Bullosa | Phase 1 | Status: COMPLETED